Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

Eli Lilly · Phase 2 · Recruiting · Enrollment 372

NCT07521631

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
HDM1005 injection dose group 1n/rn/rn/rn/r
HDM1005 injection dose group 2n/rn/rn/rn/r
HDM1005 injection dose group 3n/rn/rn/rn/r
tirzepatide injectionn/rn/rn/rn/r

Not shown

  • HDM1005 injection dose group 1: endpoint not reported
  • HDM1005 injection dose group 2: endpoint not reported
  • HDM1005 injection dose group 3: endpoint not reported
  • tirzepatide injection: endpoint not reported